Floatz logo

Elsamitrucin

Mantle Cell Lymphoma

Spectrum Pharmaceuticals, IncSmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

173 Active assets in the Mantle Cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Ruijin Hospital
Phase 4BBB
Bendamustine
Czech Lymphoma Study Group
Phase 2BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Busulphan
City of Hope Medical Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Elsamitrucin is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
57 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →